Ocugen (NASDAQ:OCGN) Shares Up 1.5% - What's Next?

Key Points

• Shares rose 1.5% to $1.38 on Monday (intraday high $1.4830) with volume ~5.09M shares, a 72% increase versus average daily volume.
• Analysts show mixed views but a consensus “Hold” rating with an average target of $7.00 (two Buys, one Sell), reflecting divergent expectations for the stock.
• Ocugen is a clinical‑stage biopharma (market cap ~$431M) with negative EPS and large losses, while its pipeline—led by OCU400 in Phase 3 for retinitis pigmentosa—offers potential upside but significant clinical and financial risk.

Ocugen, Inc. (NASDAQ:OCGN - Get Free Report)'s stock price rose 1.5% on Monday . The stock traded as high as $1.4830 and last traded at $1.38. Approximately 5,091,859 shares were traded during trading, an increase of 72% from the average daily volume of 2,967,272 shares. The stock had previously closed at $1.36.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on OCGN. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Ocugen in a research note on Friday, September 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Ocugen in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Ocugen from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ocugen currently has a consensus rating of "Hold" and an average target price of $7.00.

Ocugen Stock Up 1.5%

The business has a 50-day moving average of $1.39 and a 200 day moving average of $1.21. The company has a market capitalization of $431.00 million, a PE ratio of -6.27 and a beta of 4.54. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). Ocugen had a negative return on equity of 491.22% and a negative net margin of 1,192.18%.The firm had revenue of $3.50 million during the quarter, compared to the consensus estimate of $0.44 million. Equities research analysts predict that Ocugen, Inc. will post -0.2 earnings per share for the current year.

Institutional Investors Weigh In On Ocugen

Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Ocugen in the 1st quarter valued at approximately $28,000. Vanguard Personalized Indexing Management LLC raised its holdings in Ocugen by 48.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company's stock valued at $29,000 after buying an additional 9,791 shares during the period. BNP Paribas Financial Markets lifted its position in Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock worth $36,000 after buying an additional 13,326 shares during the last quarter. NewEdge Advisors LLC lifted its position in Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company's stock worth $36,000 after buying an additional 24,460 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft boosted its stake in Ocugen by 108.8% during the second quarter. Baader Bank Aktiengesellschaft now owns 38,142 shares of the company's stock worth $37,000 after buying an additional 19,876 shares during the period. 10.27% of the stock is owned by institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.